OneAlphaMed designed a core-plus-flex scientific messaging architecture that harmonized the central clinical narrative across 12 Asia-Pacific markets while preserving the regulatory and cultural adaptability that local teams needed.
Industry / Specialty
Pharmaceutical & Healthcare
Scale / Audience
15,000+ HCPs
Core Solutions
Co-created Certification
Time to Value
Pan-India Deployment
Stop funding clicks. Start building undisputed credibility for your brand today.
A generics manufacturer launching an immunology biosimilar simultaneously across 12 Asia-Pacific markets faced a fundamental strategic tension: the need for a consistent, scientifically defensible core narrative that would work with payers and regulators across all markets, versus the need for sufficient local flexibility to address market-specific regulatory requirements, HCP prescribing culture differences, and varying levels of biosimilar market maturity. Previous multi-market launches had resolved this tension by defaulting to full localization — with predictably inconsistent results in message quality and scientific rigour. OneAlphaMed developed a ‘Core-Plus-Flex’ messaging architecture that delivered harmonized global scientific standards with structured local adaptation — achieving a synchronized 12-market launch with a single medical-legal-regulatory approval process for the core content.
Harmonizing scientific messaging across 12 Asia-Pacific markets is not a translation challenge — it is a governance and architecture challenge that requires rethinking how pharmaceutical scientific content is designed.
The 12 target APAC markets ranged from highly mature biosimilar markets where physicians actively sought biosimilar alternatives (Australia, South Korea, Japan) to nascent markets where the concept of biosimilar switching was entirely novel to most prescribers (Vietnam, Indonesia, Bangladesh). A single global messaging strategy could not be simultaneously calibrated for both market environments — what was reassuring and evidence-sufficient in a mature market was insufficient in a nascent one.
Each of the 12 markets had distinct regulatory content requirements for promotional materials — including specific safety data disclosure formats, mandatory comparison statement restrictions, reference biologic naming conventions, and pharmacovigilance reporting language. Producing separate MLR-approved content packages for all 12 markets independently would require 12 separate approval processes — multiplying timelines and costs to the point of making a synchronized launch effectively impossible.
In previous regional launches, allowing each market to independently develop their own promotional materials had produced dramatically inconsistent scientific quality — with some markets producing sophisticated, evidence-dense HCP materials while others produced simplistic, claim-heavy content that undermined the brand's credibility with specialist prescribers who encountered content from multiple markets at regional conferences.
OneAlphaMed designed a two-layer messaging architecture that centralized what needed to be consistent and flexed what needed to be local.
OneAlphaMed's medical affairs team worked with the brand's global medical and regulatory leadership to define the 'Core Scientific Layer' — the primary efficacy and safety claims, mechanism comparison content, and clinical trial data presentation — that were identical across all 12 markets and required a single, global MLR approval cycle. This core layer was locked from local adaptation, ensuring scientific integrity and regulatory consistency across every market.
A defined 'Flex Adaptation Layer' was designed as a modular extension of the core content — allowing each market to add regulatory-required local safety disclosures, market-specific patient profiling guidance calibrated to local prescribing norms, and biosimilar market maturity-appropriate messaging depth (basic awareness for nascent markets, sophisticated switch-protocol guidance for mature markets) — without altering the core scientific narrative.
OneAlphaMed managed the central quality governance framework — reviewing all local flex layer adaptations against the core content standards before deployment — while empowering local medical affairs teams to own the execution of local regulatory submissions and HCP engagement. This hybrid model preserved the efficiency of centralization while maintaining the local ownership that drives genuine market activation.
Architecture as Strategy.
The Core-Plus-Flex architecture resolved what had previously been treated as a strategic dilemma — global consistency versus local relevance — by recognizing that it was actually an information architecture problem. By precisely defining which content elements must be consistent (scientific claims and evidence) and which can and should flex (regulatory disclosures and market maturity calibration), OneAlphaMed created a framework where global standards and local effectiveness are structurally compatible rather than inherently in tension.
The Core-Plus-Flex architecture enabled a genuinely synchronized 12-market launch at a fraction of the cost and timeline of 12 independent local launches.
The synchronized launch achieved consistent HCP awareness metrics across all 12 markets within 90 days — a commercial benchmark the brand had never previously achieved in a multi-market launch.
Received a high-quality, globally-approved scientific content foundation that eliminated the burden and uncertainty of independent content creation — freeing local medical affairs capacity to focus on HCP engagement, KOL relationship management, and regulatory liaison activities rather than medical writing and design.
Achieved a single core MLR approval cycle covering all 12 markets' primary scientific claims — reducing the total regulatory review workload by an estimated 65% compared to independent market-by-market approval and dramatically compressing the timeline between final clinical data and first HCP-facing deployment.
Achieved a documented 40% improvement in cross-market HCP awareness metric consistency compared to the brand's previous multi-market launch — eliminating the scientific quality variance that had undermined brand credibility at regional conferences and among internationally active specialist prescribers.
The Core-Flex boundary is defined through a structured content governance workshop with the brand's global Medical, Regulatory, and Legal leads early in the campaign development process. Content elements are classified using a three-question test: (1) Is this claim supported by the global clinical trial data and approved in all 12 markets? (2) Does any regulatory authority require local adaptation of this content? (3) Does market maturity context require different messaging depth? Claims that pass all three tests belong in the Core; all others are placed in the Flex layer with defined adaptation parameters.
OneAlphaMed operates a parallel review process — all 12 local flex layer adaptations are submitted for central quality review simultaneously, with a standardized 5-business-day review cycle and a standardized feedback template that minimizes back-and-forth. Local teams are provided with a detailed adaptation brief before they begin local content development, significantly reducing the rate of substantive feedback requiring major revisions.
Yes — the model is actually most valuable in exactly these situations. Markets with complex local regulatory environments (such as Japan, China, and India) typically require the most significant Flex layer adaptation — but the existence of a validated Core layer means that only the truly market-specific elements require local regulatory attention, dramatically reducing the regulatory burden compared to a full local content development approach.
+91 9811660635
info@onealphamed.com
2414, Ground Floor, Aravali Vihar, Sector 49 Faridabad, Haryana – 121001 India
Copyright © 2026 OneAlphaMed. All Rights Reserved.